In the CLEOPATRA study involving advanced HER2‐positive breast cancers treated with docetaxel, trastuzumab, and pertuzumab or placebo,31 higher TILs levels was significantly associated with improved overall survival (p = 0.0014). The gene discussed is ERBB2; the disease is breast carcinoma.